Comparative Pharmacology
Head-to-head clinical analysis: PROMAPAR versus SERENTIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMAPAR versus SERENTIL.
PROMAPAR vs SERENTIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PROMAPAR is a brand name for tramadol, a centrally acting analgesic that binds to mu-opioid receptors and inhibits serotonin and norepinephrine reuptake, modulating pain perception.
SERENTIL (mesoridazine) is a phenothiazine antipsychotic that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, and also exhibits alpha-adrenergic blocking, anticholinergic, and antihistaminic effects. It has high affinity for D2, 5-HT2A, and alpha-1 receptors.
5 mg orally twice daily, titrated up to maximum 60 mg/day in divided doses.
Oral: 50–100 mg 3 times daily; maximum 400 mg/day. IM: 25 mg every 4–6 hours.
None Documented
None Documented
Terminal elimination half-life is 2-4 hours (mean 3 hours) in adults with normal renal function; prolonged to 8-15 hours in moderate-to-severe renal impairment.
Terminal elimination half-life is approximately 24-30 hours in adults. Does not correlate well with duration of antipsychotic effect due to active metabolite formation.
Primarily renal (70-80% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for approximately 20%.
Primarily renal (70-80% as conjugated and unconjugated metabolites) and fecal (15-20%). Biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Antipsychotic
Antipsychotic